SCHEMBL5204014

SCHEMBL5204014

Fc1cccc(F)c1Cc1nc2ccccc2n1Cc1c(F)cccc1F

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
LMNA P02545 2/20 0.55
TP53 P04637 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
THRB P10828 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201300 0.83 MEN1 (0.51) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL5272035 0.81 ALDH1A1 (0.58) MEN1KMT2AALDH1A1RAB9A
SCHEMBL5204026 0.80 TNF (0.62) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL5201134 0.79 TP53 (0.57) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL5204108 0.78 TLR8 (0.40) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL5201149 0.78 TP53 (0.74) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL15567865 0.75 ALDH1A1 (0.60) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL5206952 0.74 TP53 (0.53) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL228889 0.72 LMNA (0.90) MEN1KMT2ALMNATP53SMN1; SMN2
SCHEMBL30083970 0.72 KMT2A (0.74) MEN1KMT2ALMNATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1210336-B1 SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE US HEALTH (US) 2007-04-25 EP disclosed
US-6894068-B2 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-05-17 US disclosed
US-20030191160-A1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase MICHEJDA CHRISTOPHER J (US) 2003-10-09 US disclosed
EP-1210336-A1 SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) 2002-06-05 EP disclosed
US-6369235-B1 INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2002-04-09 US disclosed
WO-2001014343-A1 SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191160-A1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase SAMHD1, DUT, TYMP MEN1 4883/4885KMT2A 402/4885LMNA 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.